Lycera has partnered with Merck & Co. to discover, develop and commercialise novel small molecules targeting T-helper 17 (Th17) cells, key mediators of inflammation that produce the pro-inflammatory cytokine IL-17, for the potential treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.